Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).

Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).

Item
http://www.wikidata.org/entity/Q34898391
Evaluation of Tumor Response after Short-Course Radiotherapy and Delayed Surgery for Rectal Cancer.Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.Perinatal Influences of Valproate on Brain and Behaviour: An Animal Model for Autism.Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II.Expression of non-secreted IL-4 is associated with HDAC inhibitor-induced cell death, histone acetylation and c-Jun regulation in human gamma/delta T-cells.Changes in the Peripheral Blood Gene Expression Profile Induced by 3 Months of Valproate Treatment in Patients with Newly Diagnosed Epilepsy.Inhibition of the HDAC/Suv39/G9a pathway restores the expression of DNA damage-dependent major histocompatibility complex class I-related chain A and B in cancer cellsSynergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53.MR imaging perfusion and diffusion analysis to assess preoperative Short Course Radiotherapy response in locally advanced rectal cancer: Standardized Index of Shape by DCE-MRI and intravoxel incoherent motion-derived parameters by DW-MRI.
P2860

Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).

Item
http://www.wikidata.org/entity/Q34898391
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Phase 1/2 study of valproic ac ...... diotherapy--rectum 3rd trial).
@ast
Phase 1/2 study of valproic ac ...... diotherapy--rectum 3rd trial).
@en
Phase 1/2 study of valproic ac ...... risk rectal cancer-V-shoRT-R3
@nl
type
label
Phase 1/2 study of valproic ac ...... diotherapy--rectum 3rd trial).
@ast
Phase 1/2 study of valproic ac ...... diotherapy--rectum 3rd trial).
@en
Phase 1/2 study of valproic ac ...... risk rectal cancer-V-shoRT-R3
@nl
prefLabel
Phase 1/2 study of valproic ac ...... diotherapy--rectum 3rd trial).
@ast
Phase 1/2 study of valproic ac ...... diotherapy--rectum 3rd trial).
@en
Phase 1/2 study of valproic ac ...... risk rectal cancer-V-shoRT-R3
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P478
P50
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
Phase 1/2 study of valproic ac ...... adiotherapy--rectum 3rd trial)
@en
P2093
P2860
P2888
P304
P31
P356
P407
P478
P50
P577
P5875
P6179
P698
P921
P932